All Updates

All Updates

icon
Filter
Funding
MapLight Therapeutics raises USD 225 million in Series C funding for Phase 2 trials of novel therapeutic candidate ML-007C-MA
Precision Medicine
Oct 29, 2023
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Microsoft launches Face Check with Microsoft Entra Verified ID
Facial Recognition
Sep 11, 2024
Funding
3DEO raises USD 3.5 million in strategic investment from Mizuho Bank
Additive Manufacturing
Sep 6, 2024
Product updates
HyperWrite launches open-source AI model Reflection 70 billion
Generative AI Applications
Sep 5, 2024
Product updates
Google begins US rollout of AI-powered Ask Photos feature
Generative AI Applications
Sep 5, 2024
Funding
Management news
HDAX Therapeutics raises USD 3.2 million in seed funding to progress pipeline and advance preclinical candidates into trials
Precision Medicine
Sep 5, 2024
Partnerships
Sequentify partners with Dexter to expand genomic diagnostics in Romania
Precision Medicine
Sep 5, 2024
Partnerships
Elevate partners with Cultivatd for European expansion
Vertical Farming
Sep 5, 2024
Product updates
Moolec confirms harvest of its genetically engineered plant-grown products
Crop Biotech
Sep 5, 2024
Precision Medicine

Precision Medicine

Oct 29, 2023

MapLight Therapeutics raises USD 225 million in Series C funding for Phase 2 trials of novel therapeutic candidate ML-007C-MA

Funding

  • MapLight Therapeutics raised  USD 225 million in a Series C funding round led by Novo Holdings, with participation from new investors, including 5AM Ventures and Cowen Healthcare Investments. This brings the company's total funding to USD to USD 268.1 million.

  • The funds are expected to be used for the development of ML-007C-MA, MapLight's novel therapeutic candidate, into Phase 2 trials for schizophrenia and Alzheimer's disease psychosis, set for 2024, and to bolster the company's other pipeline programs.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.